FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/New Study Investigates ALN-PNP and GLP1R Agonist for Treating Fatty Liver Disease
研究ライブラリに戻る

New Study Investigates ALN-PNP and GLP1R Agonist for Treating Fatty Liver Disease

November 20, 2026
Share
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、最近のニュースアイテムや臨床試験リストのAI補助要約です。ペプチド研究コミュニティにとって迅速でアクセスしやすい概要を提供することを目的としています。正確性のために常に下記リンク先の元のソースをご確認ください。

New Study Investigates ALN-PNP and GLP1R Agonist for Treating Fatty Liver Disease

A new clinical trial has started to explore the potential benefits of combining a novel peptide therapy with an existing diabetes medication in treating metabolic dysfunction-associated steatotic liver disease (MASLD), commonly known as fatty liver disease. This Phase 2a study, registered on ClinicalTrials.gov under identifier NCT07527910, is being conducted by Regeneron Pharmaceuticals and aims to shed light on the effectiveness of ALN-PNP in conjunction with a GLP1R agonist like tirzepatide.

Background

Fatty liver disease affects millions of people worldwide and can lead to serious health complications if left untreated. The condition arises when fat accumulates excessively within liver cells, causing inflammation and scarring that can eventually result in cirrhosis or liver failure. Current treatments for fatty liver disease are limited, making the development of new therapies a priority.

One promising approach involves targeting the PNPLA3 protein, which is known to contribute to the progression of MASLD. ALN-PNP, the investigational drug at the heart of this study, works by reducing the production of PNPLA3 in liver cells. By lowering levels of this problematic protein, researchers hope to decrease fat accumulation and improve overall liver health.

Key Details

The Phase 2a trial will examine how ALN-PNP performs both alone and when paired with tirzepatide, a GLP1R agonist that helps regulate blood sugar levels, appetite control, and weight management. The study aims to recruit adult patients who have homozygous PNPLA3-related MASLD, meaning they carry two copies of the gene variant associated with this condition.

Participants will be randomly assigned to receive either ALN-PNP alone, ALN-PNP in combination with tirzepatide, or a placebo. Researchers will monitor changes in liver fat content and other markers of liver health over the course of the study. The primary objective is to determine if adding tirzepatide enhances the therapeutic effects of ALN-PNP on fatty liver disease.

Key Takeaways

  • New Combination Therapy: This trial explores a novel approach by combining ALN-PNP with an existing GLP1R agonist, potentially offering a more effective treatment for MASLD.
  • Targeted Protein Reduction: ALN-PNP specifically targets the PNPLA3 protein, which is implicated in the development of fatty liver disease.
  • Clinical Trial Design: The study design includes both monotherapy and combination therapy arms to assess optimal dosing strategies and efficacy.
  • Patient Inclusion Criteria: The trial focuses on patients with homozygous PNPLA3-related MASLD, providing valuable insights for this specific patient population.

What This Means

For the peptide research community, this study represents a significant step forward in understanding how targeted protein reduction can be harnessed to treat chronic liver conditions. If successful, it could pave the way for more personalized and effective treatments tailored to patients with specific genetic risk factors. Additionally, the combination of ALN-PNP with GLP1R agonists highlights the growing trend towards multi-modal therapies that address both metabolic dysfunction and liver health simultaneously.

---

Source: ClinicalTrials.gov — Published 2026-11-18

This article is for informational purposes only and does not constitute medical advice.

編集者の注

この分析はAIツールを使用して生成され、Peptide Contacts編集部がレビューしました。正確性を追求していますが、AI生成のコンテンツには誤りや省略がある可能性があります。情報確認のために常に元のソースをご確認ください。 元のソース 詳細、方法論、データについては

Peptide Contactsは、情報提供のために-curated研究要約を提供しています。このコンテンツは医療アドバイスにはなりません。健康決定をする前に常に格付けされた医療専門家に相談してください。

Comments

Sign in to join the discussion

この記事はAIを使用して生成され、誤りや省略がある可能性があります。情報提供のために提供されていますが、医療アドバイスにはなりません。常に元のソースを確認し、格付けされた医療専門家に相談してください。